ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double‐Blind Study

OBJECTIVE: Tumor necrosis factor (TNF) and interleukin‐17A (IL‐17A) may independently contribute to the pathophysiology of rheumatoid arthritis (RA). This study sought to evaluate the safety and efficacy of ABT‐122, a novel dual variable domain immunoglobulin targeting human TNF and IL‐17A, in patie...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Arthritis Rheumatol
Prif Awduron: Genovese, Mark C., Weinblatt, Michael E., Aelion, Jacob A., Mansikka, Heikki T., Peloso, Paul M., Chen, Kun, Li, Yihan, Othman, Ahmed A., Khatri, Amit, Khan, Nasser S., Padley, Robert J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Rheumatoid Arthritis
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6704363/
https://ncbi.nlm.nih.gov/pubmed/29855172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40580
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg